Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder

Phase 2a study demonstrated rapid and substantial decrease in depressive symptoms

SPN-820 was well-tolerated with few adverse events